Australia
# |
Name |
EBT Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
57.47%
|
June 30, 2024 | USD 7.25 | -0.16% |
|
Australia |
|
2 |
22.97%
|
June 30, 2024 | USD 171.50 | 0.95% |
|
Australia |
|
3 |
16.06%
|
June 30, 2024 | USD 0.74 | 0.02% |
|
Australia |
|
4 |
5.27%
|
June 30, 2024 | USD 2.33 | 0.29% |
|
Australia |
|
5 |
1.66%
|
June 30, 2024 | USD 1.23 | 0.02% |
|
Australia |
|
6 |
0.62%
|
Dec. 31, 2023 | USD 18.31 | -0.05% |
|
Australia |
|
7 |
-4.18%
|
June 30, 2024 | USD 0.74 | 0.02% |
|
Australia |
|
8 |
-141.49%
|
June 30, 2024 | USD 2.04 | -5.56% |
|
Australia |
|
9 |
-365.26%
|
June 30, 2024 | USD 2.34 | -4.83% |
|
Australia |
|
10 |
-474.65%
|
June 30, 2024 | USD 4.80 | 5.03% |
|
Australia |
|
11 |
-1,111.87%
|
June 30, 2024 | USD 2.09 | 0.97% |
|
Australia |
|
12 |
-1,493.51%
|
June 30, 2024 | USD 1.84 | -3.30% |
|
Australia |
|
13 |
-1,680.35%
|
Dec. 31, 2023 | USD 6.22 | 1.04% |
|
Australia |
|
14 |
-153,575.00%
|
June 30, 2024 | USD 1.67 | 2.45% |
|
Australia |
|
15 |
-184,215.67%
|
June 30, 2024 | NA |
|
Australia |
The Clinical Trials company in Australia with the highest EBT Margin is Clinuvel Pharmaceuticals Limited (ASX: CUV.AX) at 57.47%.
The Clinical Trials company in Australia with the lowest EBT Margin is Opthea Limited (ASX: OPT.AX) at -184,215.67%.
The top 10 Clinical Trials companies in Australia by EBT Margin are Clinuvel Pharmaceuticals Limited, CSL Limited, Cogstate Limited, Australian Clinical Labs Limited, PolyNovo Limited, Telix Pharmaceuticals Limited, Monash IVF Group Limited, Immuron Limited, Clarity Pharmaceuticals Ltd and Alterity Therapeutics Limited.
The bottom 10 Clinical Trials companies in Australia by EBT Margin are Opthea Limited, Incannex Healthcare Limited, Anteris Technologies Ltd, Mesoblast Limited, Immutep Limited, Alterity Therapeutics Limited, Clarity Pharmaceuticals Ltd, Immuron Limited, Monash IVF Group Limited and Telix Pharmaceuticals Limited.